Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Collagen Solutions Acquired by Rosen’s Diversified

20 Oct 2020 07:03

RNS Number : 5425C
Collagen Solutions PLC
20 October 2020
 

 

 

20 October 2020

 

Collagen Solutions plc

("Collagen Solutions" or the "Company")

 

Collagen Solutions Plc Acquired by Rosen's Diversified, Inc.

 

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that today Rosen's Diversified, Inc. ("RDI") declared that its offer to acquire Collagen Solutions plc (the "Offer") had become wholly unconditional and as a result, Collagen Solutions will become part of the RDI Group.

 

RDI is a multi-billion dollar, family-owned and controlled business, headquartered in Minnesota near the Company's U.S. offices. RDI sells a broad range of food, agricultural and scientific products into more than 30 countries, across five continents, and has over 4,500 employees. Collagen Solutions will become part of RDI's life sciences division, which includes Scientific Life Solutions ("SLS"), a supplier of critical components to the bioresearch and biomedical fields.

 

Jamal Rushdy, CEO of Collagen Solutions said: "We have made tremendous progress in our vision to be the industry's first choice for regenerative biomaterials. We believe that being part of RDI will generate significant growth opportunities and create enhanced value for the benefit of all stakeholders and in particular our employees, customers and suppliers. I am optimistic and excited for the potential for continued momentum and greater opportunity for Collagen Solutions." 

 

Wade Rosen, Director of RDI and Executive Vice President of Corporate Development of SLS said: "Collagen Solutions represents an attractive strategic and cultural fit with SLS and we have been highly impressed by the long-term vision and ethos of the Company. The successful completion of the Offer will now provide a foundation for SLS to become a major tissue provider in North America, leveraging the RDI Group's local porcine and bovine harvest, logistics and distribution capabilities in the United States. Collagen's international presence will also provide a platform for SLS to extend its supply of porcine and bovine tissue into the EMEA and APAC regions."

 

England & Company, LLC and Goodbody Stockbrokers UC acted, in relation to the Offer, as joint financial advisers to Collagen Solutions. Shepherd and Wedderburn LLP acted as legal adviser to Collagen Solutions.

 

Strand Hanson and Faegre Drinker acted, in relation to the Offer, as sole financial adviser and legal adviser to RDI, respectively.

 

Enquiries:

Collagen Solutions PlcJamal Rushdy, CEOHilary Spence, CFO

via Walbrook

England & Company LLC(Joint Financial Adviser to Collagen Solutions Plc)Craig EnglandPaul Teitelbaum

Tel: +1 (212) 235-0850

Goodbody Stockbrokers UC(Rule 3 Adviser and Joint Financial Adviser to Collagen Solutions Plc)Stephen KaneChristopher McAuliffe

Tel: +353 (0) 1 667 0400

Cenkos Securities plc(Nominated Adviser and Broker to Collagen Solutions Plc)Giles BallenyMax Gould

Tel: +44 (0) 207 397 8900

Walbrook PR Ltd(Financial PR adviser to Collagen Solutions Plc)Anna Dunphy

Tel: +44 (0) 207 933 8780or collagen@walbrookpr.com

Mob: +44 (0) 7876 741 001

Rosen's Diversified, Inc.David Krawitz, Director of Strategy, Operations and Sales

Tel: +1 (612) 406-5181

Strand Hanson Limited(Financial Adviser to Rosen's Diversified, Inc.)Stuart FaulknerMatthew ChandlerJames DanceJack Botros

Tel: +44 (0) 207 409 3494

Important Notice

England & Company LLC, through its wholly owned subsidiary, England Securities, LLC, is acting as joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of England & Company LLC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither England & Company LLC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of England & Company LLC in connection with this announcement, any statement contained herein or otherwise.

Goodbody Stockbrokers UC, trading as Goodbody, which is regulated in Ireland by the Central Bank of Ireland and in the UK by the Financial Conduct Authority, is acting as sole Rule 3 adviser and joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Goodbody Stockbrokers UC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Goodbody Stockbrokers UC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goodbody Stockbrokers UC in connection with this announcement, any statement contained herein or otherwise.

Cenkos Securities plc, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as nominated adviser and broker to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Cenkos Securities plc nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Cenkos Securities plc nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cenkos Securities plc in connection with this announcement, any statement contained herein or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQDGBDGLXBDGGC
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.